跳至主要内容
临床试验/ACTRN12621000383864
ACTRN12621000383864进行中(未招募)未知

Analysing compliance with Calcium and Vitamin D supplementations in Cancer patients receiving bone resorptive agents.

Icon Cancer Foundation0 个研究点目标入组 112 人开始时间: 2021年4月7日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
112

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients over the age of 18 treated at Icon Cancer Centre sites where Denosumab, Pamidronate or Zoledronic acid has been prescribed between August 2021 and recruitment period of 24 months in total or until goal participant numbers have been reached.

排除标准

  • Patients with hyperglycemia of malignancy;
  • Patients with history of osteoporosis.
  • Patients participating in other clinical trials

研究者

相似试验